SCHEMBL4767004

SCHEMBL4767004

N#Cc1cc(Nc2ccc(Nc3ccccc3)cc2)c2cc(F)ncc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.43
ABCB1 P08183 2/20 0.43
ACP1 P24666 6/20 0.39
MAP2K1 Q02750 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA1 P30542 1/20 0.39
EGFR P00533 1/20 0.37
RAF1 P04049 1/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.35
KDR P35968 1/20 0.35
CHEK1 O14757 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776048 0.90 NPC1 (0.41) ABCG2ABCB1ACP1EGFRMAPT
SCHEMBL4769773 0.90 MAP2K1 (0.44) ABCG2ABCB1ACP1MAP2K1ADORA3
SCHEMBL4766924 0.90 ABCB1 (0.39) ABCG2ABCB1ACP1MAP2K1ADORA3
SCHEMBL4769765 0.88 SLC2A1 (0.42) ABCG2ABCB1ACP1EGFRKDM4E
SCHEMBL4775748 0.88 MAPKAPK2 (0.45) ABCG2ABCB1ACP1MAP2K1EGFR
SCHEMBL4767045 0.85 MAP2K1 (0.46) ABCG2ABCB1ACP1MAP2K1EGFR
SCHEMBL4776121 0.85 KCNQ3 (0.39) ABCG2ABCB1EGFRLMNAMAPT
SCHEMBL4777976 0.84 FADS1 (0.43) EGFR
SCHEMBL4766938 0.75 MAP2K1 (0.64) MAP2K1EGFRRAF1
SCHEMBL19610527 0.72 CYP1A2 (0.43) ABCG2ABCB1ACP1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432279-B2 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2008-10-07 US disclosed
EP-1881981-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-01-30 EP disclosed
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-12-07 US disclosed
WO-2006124944-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CNKSR1, DTYMK ABCG2 3881/4885ABCB1 2496/4885ACP1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.